NKMAX Co., Ltd.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Seongnam-Si Korea, Republic of (2002)

Organization Overview

First Clinical Trial
2019
NCT03941262
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

ATGen Canada Inc | NKMax America, Inc. | NKMAX Co., Ltd.